Related Experiment Videos
[Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics]
S Choufane1, E Lobjoie, F Tinturier
1Service d'anesthésie-réanimation, CHU Saint-Louis, Paris, France.
Objective:
To assess the pharmacokinetics of a single dose of teicoplanin in critically ill patients treated with continuous arteriovenous haemofiltration (CAVH).
Study Design:
Prospective open clinical study.
Patients:
Eleven patients with acute renal insufficiency and suspected of a Gram negative infection.
Method:
After injection of teicoplanin, 6 mg.kg-1 over 30 minutes the plasma and haemofiltrate concentrations were measured over 24 hours with high power liquid chromatography (HPLC).
Results:
In plasma, the mean half-life of the first phase was 0.6 +/- 0.2 hour and terminal half-life was 16.4 +/- 5 8 hours, total clearance 30.4 +/- 7.1 mL.h-1.kg-1, volume of distribution was 0.7 +/- 0.3 L.kg-1 and the mean resident time 19.2 +/- 7.4 hours. In the haemofiltrate, the amount of teicoplanin eliminated after 24 hours was less than 1% in seven patients, between 1.8 and 3.7% in three and reached 7% in one patient.
Conclusion:
During CAVH, the elimination of a single dose of teicoplanin in the haemofiltrate is low.